Synonym
ZYJ-34c; ZYJ 34c; ZYJ34c;
IUPAC/Chemical Name
2-((3,3-dimethylbutanoyl)isoleucyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
InChi Key
DMFYWVSGUMHBCM-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H42N4O7/c1-7-19(2)28(33-26(36)16-31(3,4)5)30(39)35-17-21-14-24(42-18-27(37)34-40)11-8-20(21)15-25(35)29(38)32-22-9-12-23(41-6)13-10-22/h8-14,19,25,28,40H,7,15-18H2,1-6H3,(H,32,38)(H,33,36)(H,34,37)
SMILES Code
CCC(C(C(N1CC2=C(CC1C(NC3=CC=C(OC)C=C3)=O)C=CC(OCC(NO)=O)=C2)=O)NC(CC(C)(C)C)=O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
582.69
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. Anticancer Drugs. 2014 Aug;25(7):767-77. doi: 10.1097/CAD.0000000000000101. PubMed PMID: 24686006.
2: Zhang Y, Inks ES, Zhu M, Chou CJ, Fang H, Li M, Shen Y, Yi F, Xu W. Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study. RSC Adv. 2013 Nov 21;3(43). doi: 10.1039/C3RA43249A. PubMed PMID: 24273644; PubMed Central PMCID: PMC3836556.
3: Zhang Y, Liu C, Chou CJ, Wang X, Jia Y, Xu W. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem Biol Drug Des. 2013 Aug;82(2):125-30. doi: 10.1111/cbdd.12144. Epub 2013 Jul 1. PubMed PMID: 23581848; PubMed Central PMCID: PMC3723752.
4: Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem. 2011 Aug 11;54(15):5532-9. doi: 10.1021/jm200577a. Epub 2011 Jul 11. PubMed PMID: 21714538.